Published in Trends Neurosci on November 08, 2010
Dynamic functional connectivity: promise, issues, and interpretations. Neuroimage (2013) 4.39
Toward a neuroimaging treatment selection biomarker for major depressive disorder. JAMA Psychiatry (2013) 4.12
Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. Nat Rev Drug Discov (2011) 2.65
From stress to inflammation and major depressive disorder: a social signal transduction theory of depression. Psychol Bull (2014) 2.39
Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry (2013) 1.92
Subcallosal cingulate deep brain stimulation for treatment-resistant unipolar and bipolar depression. Arch Gen Psychiatry (2012) 1.83
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A (2012) 1.79
Large-Scale Network Dysfunction in Major Depressive Disorder: A Meta-analysis of Resting-State Functional Connectivity. JAMA Psychiatry (2015) 1.76
Ketamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug action. PLoS One (2012) 1.27
Dynamic network communication as a unifying neural basis for cognition, development, aging, and disease. Biol Psychiatry (2015) 1.27
GABAA receptor subtypes: Therapeutic potential in Down syndrome, affective disorders, schizophrenia, and autism. Annu Rev Pharmacol Toxicol (2013) 1.20
The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Front Hum Neurosci (2014) 1.16
The role of ketamine in treatment-resistant depression: a systematic review. Curr Neuropharmacol (2014) 1.10
Pretreatment brain states identify likely nonresponse to standard treatments for depression. Biol Psychiatry (2013) 1.05
Dynamic functional connectomics signatures for characterization and differentiation of PTSD patients. Hum Brain Mapp (2013) 0.98
Potential utility of optogenetics in the study of depression. Biol Psychiatry (2012) 0.91
A meta-analysis of changes in brain activity in clinical depression. Front Hum Neurosci (2015) 0.87
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol (2016) 0.86
Network destabilization and transition in depression: New methods for studying the dynamics of therapeutic change. Clin Psychol Rev (2015) 0.86
Distracted and down: neural mechanisms of affective interference in subclinical depression. Soc Cogn Affect Neurosci (2014) 0.86
Major depression epidemiology from a diathesis-stress conceptualization. BMC Psychiatry (2013) 0.85
Introducing co-activation pattern metrics to quantify spontaneous brain network dynamics. Neuroimage (2015) 0.84
Dynamic functional connectivity revealed by resting-state functional near-infrared spectroscopy. Biomed Opt Express (2015) 0.84
Using biomarkers to predict treatment response in major depressive disorder: evidence from past and present studies. Dialogues Clin Neurosci (2014) 0.84
Why are cortical GABA neurons relevant to internal focus in depression? A cross-level model linking cellular, biochemical and neural network findings. Mol Psychiatry (2014) 0.84
Treatment decisions based on scalar and functional baseline covariates. Biometrics (2015) 0.84
Multistage drug effects of ketamine in the treatment of major depression. Eur Arch Psychiatry Clin Neurosci (2014) 0.82
Characterizing and Differentiating Brain State Dynamics via Hidden Markov Models. Brain Topogr (2014) 0.82
Understanding the relationship between co-occurring PTSD and MDD: symptom severity and affect. J Anxiety Disord (2011) 0.81
Understanding heterogeneity in PTSD: fear, dysphoria, and distress. Depress Anxiety (2013) 0.81
Behavioral activation for the treatment of atypical depression: a pilot open trial. Behav Modif (2011) 0.81
Whole-brain functional connectivity during emotional word classification in medication-free Major Depressive Disorder: Abnormal salience circuitry and relations to positive emotionality. Neuroimage Clin (2013) 0.81
Facilitating emotional processing in depression: the application of exposure principles. Curr Opin Psychol (2015) 0.80
Mice genetically depleted of brain serotonin do not display a depression-like behavioral phenotype. ACS Chem Neurosci (2014) 0.80
Highly penetrant alterations of a critical region including BDNF in human psychopathology and obesity. Arch Gen Psychiatry (2012) 0.80
Rapid antidepressants stimulate the decoupling of GABA(B) receptors from GIRK/Kir3 channels through increased protein stability of 14-3-3η. Mol Psychiatry (2015) 0.79
Lesion analysis for cingulotomy and limbic leucotomy: comparison and correlation with clinical outcomes. J Neurosurg (2013) 0.79
Mechanisms underlying the antidepressant response and treatment resistance. Front Behav Neurosci (2014) 0.78
Antidepressant, anxiolytic and procognitive effects of rivastigmine and donepezil in the chronic mild stress model in rats. Psychopharmacology (Berl) (2016) 0.78
Event-related potentials reveal preserved attention allocation but impaired emotion regulation in patients with epilepsy and comorbid negative affect. PLoS One (2015) 0.77
Chronic Fluoxetine Induces the Enlargement of Perforant Path-Granule Cell Synapses in the Mouse Dentate Gyrus. PLoS One (2016) 0.77
The Therapeutic Potential of Psychedelic Drugs: Past, Present and Future. Neuropsychopharmacology (2017) 0.76
Intrinsic functional connectivity in late-life depression: trajectories over the course of pharmacotherapy in remitters and non-remitters. Mol Psychiatry (2016) 0.76
Multidimensional prediction of treatment response to antidepressants with cognitive control and functional MRI. Brain (2017) 0.76
Neuromodulation for treatment-resistant depression. F1000 Med Rep (2012) 0.76
What is Depression in Epilepsy? Front Neurol (2011) 0.75
Histone Lysine Demethylases of JMJD2 or KDM4 Family are Important Epigenetic Regulators in Reward Circuitry in the Etiopathology of Depression. Neuropsychopharmacology (2016) 0.75
Engaging Research Domain Criteria (RDoC): Neurocircuitry in Search of Meaning. Schizophr Bull (2016) 0.75
Just Swap Out of Negative Vibes? Rumination and Inhibition Deficits in Major Depressive Disorder: Data from Event-Related Potentials Studies. Front Psychol (2016) 0.75
Investigational drugs in recent clinical trials for treatment-resistant depression. Expert Rev Neurother (2017) 0.75
Maternal immune activation epigenetically regulates hippocampal serotonin transporter levels. Neurobiol Stress (2016) 0.75
Role of psilocybin in the treatment of depression. Ther Adv Psychopharmacol (2016) 0.75
Interventional psychiatry: why now? J Clin Psychiatry (2014) 0.75
Prodepressant- and anxiogenic-like effects of serotonin-selective, but not noradrenaline-selective, antidepressant agents in mice lacking α2-containing GABAA receptors. Behav Brain Res (2017) 0.75
Serotonin and brain function: a tale of two receptors. J Psychopharmacol (2017) 0.75
Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry (2005) 58.92
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry (2006) 14.15
Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry (2006) 12.41
Deep brain stimulation for treatment-resistant depression. Neuron (2005) 12.39
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry (2006) 11.84
mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science (2010) 10.97
Antidepressant effects of ketamine in depressed patients. Biol Psychiatry (2000) 10.91
A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med (2000) 10.25
Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry (2000) 9.02
Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol (2005) 8.49
Pituitary-adrenal and autonomic responses to stress in women after sexual and physical abuse in childhood. JAMA (2000) 7.21
Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials (2004) 6.64
The molecular neurobiology of depression. Nature (2008) 6.51
Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med (2006) 6.00
Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry (2007) 5.59
Neurocircuitry of mood disorders. Neuropsychopharmacology (2010) 5.57
The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry (1965) 5.09
Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet (2003) 4.55
Increased amygdala and decreased dorsolateral prefrontal BOLD responses in unipolar depression: related and independent features. Biol Psychiatry (2006) 4.37
Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry (2002) 4.24
Can't shake that feeling: event-related fMRI assessment of sustained amygdala activity in response to emotional information in depressed individuals. Biol Psychiatry (2002) 4.08
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry (2010) 4.00
Deep brain stimulation to reward circuitry alleviates anhedonia in refractory major depression. Neuropsychopharmacology (2007) 3.81
Lithium salts in the treatment of psychotic excitement. Med J Aust (1949) 3.73
Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Arch Gen Psychiatry (2005) 3.46
Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Arch Gen Psychiatry (2005) 3.23
The treatment of depressive states with G 22355 (imipramine hydrochloride). Am J Psychiatry (1958) 3.18
Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry (2010) 3.14
The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol (1999) 3.10
The current state of cognitive therapy: a 40-year retrospective. Arch Gen Psychiatry (2005) 3.07
Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry (2002) 3.01
Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression. Biol Psychiatry (2008) 3.00
Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE). Arch Gen Psychiatry (2006) 2.93
Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression. Biol Psychiatry (2008) 2.86
Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry (2007) 2.84
Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study. Lancet Neurol (2008) 2.83
A multidimensional model of obsessive-compulsive disorder. Am J Psychiatry (2005) 2.75
Remission of major depression under deep brain stimulation of the lateral habenula in a therapy-refractory patient. Biol Psychiatry (2010) 2.71
Use of FMRI to predict recovery from unipolar depression with cognitive behavior therapy. Am J Psychiatry (2006) 2.69
Six-year outcome of cognitive behavior therapy for prevention of recurrent depression. Am J Psychiatry (2004) 2.68
A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain (2008) 2.65
Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study. Am J Psychiatry (2010) 2.56
Nucleus accumbens deep brain stimulation decreases ratings of depression and anxiety in treatment-resistant depression. Biol Psychiatry (2010) 2.46
Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide. Neurosci Biobehav Rev (2009) 2.44
The biological basis of an antidepressant response to sleep deprivation and relapse: review and hypothesis. Am J Psychiatry (1990) 2.41
The neural basis of mood-congruent processing biases in depression. Arch Gen Psychiatry (2002) 2.35
Cognitive reactivity to sad mood provocation and the prediction of depressive relapse. Arch Gen Psychiatry (2006) 2.33
Chlorpromazine in the treatment of neuropsychiatric disorders. J Am Med Assoc (1954) 2.33
Daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of major depression: clinical predictors of outcome in a multisite, randomized controlled clinical trial. Neuropsychopharmacology (2008) 2.31
Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry (2005) 2.24
Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord (2010) 2.20
Effect of concomitant pharmacotherapy on electroconvulsive therapy outcomes: short-term efficacy and adverse effects. Arch Gen Psychiatry (2009) 2.08
Interpersonal and social rhythm therapy: managing the chaos of bipolar disorder. Biol Psychiatry (2000) 2.06
Unilateral pedunculopontine stimulation improves falls in Parkinson's disease. Brain (2009) 2.05
Targeted electrode-based modulation of neural circuits for depression. J Clin Invest (2009) 2.03
Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry (2005) 1.90
Minding one's emotions: mindfulness training alters the neural expression of sadness. Emotion (2010) 1.81
The cognitive effects of electroconvulsive therapy in community settings. Neuropsychopharmacology (2006) 1.71
A systematic review of research findings on the efficacy of interpersonal therapy for depressive disorders. Eur Arch Psychiatry Clin Neurosci (2004) 1.67
Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol Psychiatry (2010) 1.66
Efficacy of interpersonal psychotherapy as a maintenance treatment of recurrent depression. Contributing factors. Arch Gen Psychiatry (1991) 1.65
The treatment of manic psychoses by the administration of lithium salts. J Neurol Neurosurg Psychiatry (1954) 1.58
Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. J Clin Psychiatry (2005) 1.57
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases. J Clin Psychiatry (2007) 1.54
A controlled trial of iproniazid in the treatment of endogenous depression. J Ment Sci (1960) 1.54
The psychoses: cluster 3 of the proposed meta-structure for DSM-V and ICD-11. Psychol Med (2009) 1.52
Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry (2006) 1.51
Treatment of dystonia with deep brain stimulation. Neurotherapeutics (2008) 1.50
Sixty years of psychosurgery: its present status and its future. Aust N Z J Psychiatry (1997) 1.39
A patient with a resistant major depression disorder treated with deep brain stimulation in the inferior thalamic peduncle. Neurosurgery (2005) 1.35
Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. J Clin Psychiatry (2006) 1.33
Columbia atypical depression. A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry Suppl (1993) 1.26
Norepinephrine in depressive reactions. A review. Arch Gen Psychiatry (1965) 1.24
A meta-analysis of repetitive transcranial magnetic stimulation in the treatment of depression. Psychopharmacol Bull (2001) 1.24
Schizophrenia: moving beyond monoamine antagonists. Mol Interv (2008) 1.17
Durability of antidepressant response to vagus nerve stimulation (VNS). Int J Neuropsychopharmacol (2007) 1.16
Bipolar depression: overview and commentary. Harv Rev Psychiatry (2010) 1.12
Vagus nerve stimulation for depression: efficacy and safety in a European study. Psychol Med (2008) 1.09
Substance P serum levels are increased in major depression: preliminary results. Biol Psychiatry (2003) 1.08
The role of beta-endorphin in the pathophysiology of major depression. Neuropeptides (2009) 1.08
Cognitive declines one year after unilateral deep brain stimulation surgery in Parkinson's disease: a controlled study using reliable change. Clin Neuropsychol (2008) 1.05
Depression and endocrine disorders: focus on the thyroid and adrenal system. Br J Psychiatry Suppl (1996) 0.99
Three and six-month outcome following courses of either ECT or rTMS in a population of severely depressed individuals--preliminary report. Biol Psychiatry (2002) 0.99
Deep brain stimulation and tremor. Neurotherapeutics (2008) 0.98
Cellular mechanisms underlying affective resiliency: the role of glucocorticoid receptor- and mitochondrially-mediated plasticity. Brain Res (2009) 0.93
Bilateral epidural prefrontal cortical stimulation for treatment-resistant depression. Biol Psychiatry (2010) 0.92
Cognitive-behavioral management of drug-resistant major depressive disorder. J Clin Psychiatry (1997) 0.91
Rethinking depression and the actions of antidepressants: uncovering the links between the neural and behavioral elements. J Affect Disord (2010) 0.90
Atypical depression: useful concept, but it's time to revise the DSM-IV criteria. Neuropsychopharmacology (2009) 0.88
Comparison of iproniazid with other amine oxidase inhibitors, including W-1544, JB-516, RO 4-1018, and RO 5-0700. Ann N Y Acad Sci (1959) 0.87
Symptom subtypes of obsessive-compulsive disorder: are they relevant for treatment? Aust N Z J Psychiatry (2008) 0.86
Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression. Biol Psychiatry (2003) 0.86
THE PHARMACOLOGY AND BIOCHEMISTRY OF DEPRESSION. Dis Nerv Syst (1964) 0.82
Emerging treatments for depression. Expert Opin Pharmacother (2006) 0.80
Efficacy and safety of antidepressant monotherapy in the treatment of bipolar-II depression. Int Clin Psychopharmacol (2007) 0.78
A historical perspective. The rise and fall of prefrontal lobotomy. Adv Neurol (1995) 0.77
The Origin and Nature of the Hypoglycemic Therapy of the Psychoses. Bull N Y Acad Med (1937) 0.77
Artificial Fever as a Therapeutic Procedure. Cal West Med (1936) 0.76
Chlorpromazine in psychiatric illness. N Engl J Med (1954) 0.76
Toward discovery science of human brain function. Proc Natl Acad Sci U S A (2010) 15.22
Allele-specific FKBP5 DNA demethylation mediates gene-childhood trauma interactions. Nat Neurosci (2012) 4.71
Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. Nat Neurosci (2007) 4.46
Toward a neuroimaging treatment selection biomarker for major depressive disorder. JAMA Psychiatry (2013) 4.12
A whole brain fMRI atlas generated via spatially constrained spectral clustering. Hum Brain Mapp (2011) 3.75
Neurobiological mechanisms of the placebo effect. J Neurosci (2005) 3.41
A multicenter pilot study of subcallosal cingulate area deep brain stimulation for treatment-resistant depression. J Neurosurg (2011) 3.30
Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression. Biol Psychiatry (2008) 3.00
Posttraumatic stress disorder: a state-of-the-science review. J Psychiatr Res (2005) 2.61
Deep brain stimulation for treatment-resistant depression: follow-up after 3 to 6 years. Am J Psychiatry (2011) 2.46
Harnessing neuroplasticity for clinical applications. Brain (2011) 2.45
Disease state prediction from resting state functional connectivity. Magn Reson Med (2009) 2.37
Misuse of the FDA's humanitarian device exemption in deep brain stimulation for obsessive-compulsive disorder. Health Aff (Millwood) (2011) 2.34
VNS therapy in treatment-resistant depression: clinical evidence and putative neurobiological mechanisms. Neuropsychopharmacology (2006) 2.24
Unmasking disease-specific cerebral blood flow abnormalities: mood challenge in patients with remitted unipolar depression. Am J Psychiatry (2002) 2.23
Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial. Am J Psychiatry (2007) 2.15
A tractography analysis of two deep brain stimulation white matter targets for depression. Biol Psychiatry (2008) 1.90
Functional neuroanatomical substrates of altered reward processing in major depressive disorder revealed by a dopaminergic probe. Arch Gen Psychiatry (2005) 1.85
Risk and resilience markers in bipolar disorder: brain responses to emotional challenge in bipolar patients and their healthy siblings. Am J Psychiatry (2006) 1.84
Subcallosal cingulate deep brain stimulation for treatment-resistant unipolar and bipolar depression. Arch Gen Psychiatry (2012) 1.83
Corticolimbic brain reactivity to social signals of threat before and after sertraline treatment in generalized social phobia. Biol Psychiatry (2012) 1.78
Neural stimulation successfully treats depression in patients with prior ablative cingulotomy. Am J Psychiatry (2008) 1.49
Receptor architecture of human cingulate cortex: evaluation of the four-region neurobiological model. Hum Brain Mapp (2009) 1.48
Deep brain stimulation for psychiatric disorders. Annu Rev Neurosci (2011) 1.47
Cerebral metabolic correlates as potential predictors of response to anterior cingulotomy for treatment of major depression. J Neurosurg (2003) 1.39
Defining the neural circuitry of depression: toward a new nosology with therapeutic implications. Biol Psychiatry (2007) 1.39
Scientific and ethical issues related to deep brain stimulation for disorders of mood, behavior, and thought. Arch Gen Psychiatry (2009) 1.33
An fMRI study investigating cognitive modulation of brain regions associated with emotional processing of visual stimuli. Neuropsychologia (2003) 1.29
State and trait influences on mood regulation in bipolar disorder: blood flow differences with an acute mood challenge. Biol Psychiatry (2003) 1.28
Predictors of nonresponse to cognitive behavioural therapy or venlafaxine using glucose metabolism in major depressive disorder. J Psychiatry Neurosci (2009) 1.16
Treatment resistant depression as a failure of brain homeostatic mechanisms: implications for deep brain stimulation. Exp Neurol (2009) 1.12
Depression beliefs, treatment preference, and outcomes in a randomized trial for major depressive disorder. J Psychiatr Res (2011) 1.12
Decreased cortical representation of genital somatosensory field after childhood sexual abuse. Am J Psychiatry (2013) 1.10
Predictors of remission in depression to individual and combined treatments (PReDICT): study protocol for a randomized controlled trial. Trials (2012) 1.06
Tractography-activation models applied to subcallosal cingulate deep brain stimulation. Brain Stimul (2013) 0.99
Neuropsychological impact of Cg25 deep brain stimulation for treatment-resistant depression: preliminary results over 12 months. J Nerv Ment Dis (2008) 0.96
Exploratory structural equation modeling of resting-state fMRI: applicability of group models to individual subjects. Neuroimage (2009) 0.96
Beyond Depression: Towards a Process-Based Approach to Research, Diagnosis, and Treatment. Clin Psychol (New York) (2011) 0.95
Personality influences limbic-cortical interactions during sad mood induction. Neuroimage (2003) 0.94
Deep brain stimulation for treatment-resistant depression. Am J Psychiatry (2010) 0.92
Frontal theta cordance predicts 6-month antidepressant response to subcallosal cingulate deep brain stimulation for treatment-resistant depression: a pilot study. Neuropsychopharmacology (2012) 0.89
Mourning and melancholia revisited: correspondences between principles of Freudian metapsychology and empirical findings in neuropsychiatry. Ann Gen Psychiatry (2008) 0.89
Neuroimaging and psychiatry: the long road from bench to bedside. Hastings Cent Rep (2014) 0.87
Ethical guidance for the management of conflicts of interest for researchers, engineers and clinicians engaged in the development of therapeutic deep brain stimulation. J Neural Eng (2011) 0.87
Neuronal coding of implicit emotion categories in the subcallosal cortex in patients with depression. Biol Psychiatry (2013) 0.86
Relationship between regional brain metabolism, illness severity and age in depressed subjects. Psychiatry Res (2007) 0.86
Enrolling in deep brain stimulation research for depression: influences on potential subjects' decision making. Depress Anxiety (2011) 0.85
Asymmetrical contribution of brain structures to treatment-resistant depression as illustrated by effects of right subgenual cingulum stimulation. J Neuropsychiatry Clin Neurosci (2010) 0.84
The ethics of research on deep brain stimulation for depression: decisional capacity and therapeutic misconception. Ann N Y Acad Sci (2012) 0.84
Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial. Trials (2014) 0.83
Changes in regional cerebral blood flow following mood challenge in drug-free, remitted patients with unipolar depression. Depress Anxiety (2007) 0.83
Practical considerations in the development and refinement of subcallosal cingulate white matter deep brain stimulation for treatment-resistant depression. World Neurosurg (2012) 0.83
Neural representation of maternal face processing: a functional magnetic resonance imaging study. Can J Psychiatry (2007) 0.83
The role of imaging in United States courtrooms. Neuroimaging Clin N Am (2007) 0.82
Differential neural activity and connectivity for processing one's own face: a preliminary report. Psychiatry Res (2011) 0.80
Penfield revisited? Understanding and modifying behavior by deep brain stimulation for PD. Neurology (2002) 0.78
Neuropsychological function before and after subcallosal cingulate deep brain stimulation in patients with treatment-resistant depression. Depress Anxiety (2014) 0.78
Brain stimulation in neurology and psychiatry: perspectives on an evolving field. Ann N Y Acad Sci (2012) 0.77
Neuromodulation for treatment-resistant depression. F1000 Med Rep (2012) 0.76
The Illness Density Index (IDI): A longitudinal measure of treatment efficacy. Clin Trials (2012) 0.76
Tolerability of the dexamethasone-corticotropin releasing hormone test in major depressive disorder. J Psychiatr Res (2010) 0.75
Microfabricated polymer-based neural interface for electrical stimulation/recording, drug delivery, and chemical sensing--development. Conf Proc IEEE Eng Med Biol Soc (2013) 0.75
Erratum: Resting-state connectivity biomarkers define neurophysiological subtypes of depression. Nat Med (2017) 0.75
Persistent auditory hallucinations that are unresponsive to antipsychotic drugs. Am J Psychiatry (2006) 0.75
Is late-life depression a predictor of Alzheimer's disease? Results from a historical cohort study. Int J Geriatr Psychiatry (2005) 0.75